Imara wraps up a phase IIa in sickle cell with mixed results Jan. 6, 2021 By Lee Landenberger Imara Inc. reported a mixed bag of phase IIa study data for its lead candidate, IMR-687, for treating sickle cell disease in adults, bringing an end to a study that the company found cumbersome and that eventually stung its stock.Read More
Geron initiates phase III study of imetelstat in myelofibrosis refractory to JAK inhibitors Dec. 28, 2020
DISC-0974 decreases hepcidin and increases transferrin saturation in inflammation models Dec. 28, 2020
RSS
